News

Shire said that the lawsuit results from an Abbreviated New Drug Application (ANDA) filed by Teva for generic versions of 1mg, 2mg, 3mg and 4mg guanfacine hydrochloride extended

Symphogen believes Sympress II technology could supply drug product for large indications such as cancer and infectious disease. The Sympress II results demonstrated single-batch production of compositions with

Reportedly, the entire facility is spread across 5000 sqft for formulation, development and analytical development and is designed and equipped to meet the stringent international standards. Bafna Pharmaceuticals

Intercell has posted a net loss of EUR18.37m for the full year 2009, or EUR0.39 per diluted share, compared to net income of EUR17.17m, or EUR0.37 per diluted

Pro-Tect Pharmaceuticals said that the acquired patents would enable it to provide efficient, effective drug delivery platforms for three essential needs i.e., a gastro-retentive platform for drugs that

According to the agreement, Cytovance will lead the cell culture process optimization, recovery and purification development, CGMP manufacturing and also technical and regulatory support to facilitate Selexys’ clinical

Earlier, Sanofi-Aventis has settled three lawsuits in the US over Eloxatin against some generics manufacturers namely Teva Pharmaceuticals USA, Fresenius Kabi (formerly Dabur), Sandoz, Mayne/Hospira, MN/Par and Actavis,

The eSensor Thrombophilia Risk Test is for use on the company’s XT-8 system, a versatile DNA detection platform for hospital and reference laboratories. TRT can be configured to

Amlodipine benazepril is indicated for the treatment of hypertension in patients not adequately controlled with either agent and is taken once daily. Dr Reddy’s product is available in